TORONTO, March 6 /CNW/ - Spectral Diagnostics Inc. (TSX:SDI) today
announced that Mr. Anthony Bihl has been appointed to the Company's Board of
"As the former CEO of Siemens Medical Solutions Diagnostics, a
combination of the former Bayer Diagnostics and Diagnostic Products
Corporation, Mr. Bihl will be a valuable addition to our Board," said Dr. Paul
Walker, President and CEO of Spectral Diagnostics. "Mr. Bihl is a 25 year
veteran in the field of diagnostics and is well-suited to advise Spectral on
our global commercialization strategy of the EAA(TM) Endotoxin Activity Assay,
the only FDA cleared diagnostic for the measurement of endotoxin."
Mr. Bihl has more than 25 years of experience with diagnostic products,
having held leadership roles in global healthcare businesses, including a
broad base of operational and executive positions in large and medium
multinational healthcare firms. Before his role as CEO of Siemens Medical
Solutions Diagnostics, Mr. Bihl served in senior leadership roles at Bayer
Healthcare Diagnostics, having held the roles of Senior VP of Finance and
Administration and President, responsible for all aspects of this worldwide
business Division. Prior to his tenure at Bayer, Mr. Bihl gained extensive
operational experience through more than 20 years at E.I. DuPont Inc. His
final role at DuPont was as Plant Manager for medical instrument
Mr. Bihl received a Bachelor's Degree in Business Administration from
Pennsylvania State University, and is a member of the Board of Directors for
Adnavance Technologies Inc.
About Spectral Diagnostics
Spectral is a developer of innovative technologies for comprehensive
disease management. Spectral's lead product is its EAA(TM) Endotoxin Activity
Assay, the only FDA approved diagnostic for the measurement of endotoxin.
Spectral technologies provide accurate and timely information to clinicians
enabling the early initiation of appropriate and targeted therapy. Spectral is
listed on TSX under the symbol SDI.
Information in this news release that is not current or historical
factual information may constitute forward-looking information within the
meaning of securities laws. Implicit in this information, particularly in
respect of the future outlook of Spectral and anticipated events or results,
are assumptions based on beliefs of Spectral's senior management as well as
information currently available to it. While these assumptions were considered
reasonable by Spectral at the time of preparation, they may prove to be
incorrect. Readers are cautioned that actual results are subject to a number
of risks and uncertainties, including the availability of funds and resources
to pursue R&D projects, the successful and timely completion of clinical
studies, the ability of Spectral to take advantage of business opportunities
in the biomedical industry, the granting of necessary approvals by regulatory
authorities as well as general economic, market and business conditions, and
could differ materially from what is currently expected.
The TSX has not reviewed and does not accept responsibility for the
adequacy or accuracy of this statement.
For further information:
For further information: Dr. Paul Walker, President & CEO, (416)
626-3233 ex. 2100; James Smith, Investor Relations, (416) 815-0700 ext. 229,